All In Biotech

Drug Trial Radar · NCT04886596

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 26,675 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

26,675

Actual

Start

May 25, 2021

Primary completion

Apr 11, 2022

Study completion May 31, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • PlaceboBiological

    Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.

  • RSVPreF3 OA vaccineBiological

    RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA VaccineTime frame: From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]

Locations

277 sites in 17 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Laguna Hills, California

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Jacksonville, Florida

  • GSK Investigational Site

    Lake City, Florida

  • GSK Investigational Site

    Melbourne, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pinellas Park, Florida

  • GSK Investigational Site

    The Villages, Florida

  • GSK Investigational Site

    Weeki Wachee, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Evansville, Indiana

  • GSK Investigational Site

    Mishawaka, Indiana

  • GSK Investigational Site

    El Dorado, Kansas

  • GSK Investigational Site

    Newton, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Wichita, Kansas

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Rockville, Maryland

  • GSK Investigational Site

    Richfield, Minnesota

  • GSK Investigational Site

    Kansas City, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Henderson, Nevada

  • GSK Investigational Site

    Binghamton, New York

  • GSK Investigational Site

    Jamaica, New York

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Rocky Mount, North Carolina

  • GSK Investigational Site

    Salisbury, North Carolina

  • GSK Investigational Site

    Statesville, North Carolina

Showing 40 of 277 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.